Urol. praxi, 2013; 14(2): 63-66
Non-surgical treatment of metastatic renal cell carcinoma
- Onkologická klinika 1. LF UK a VFN, Katedra klinické onkologie IPVZ Praha
The treatment of advanced and metastatic renal cell cancer is based on systemic therapy in combination with cytoreductive local approaches.
Cytokines, used in the past, may currently be beneficial for patients in a good prognostic group, but molecularly targeted
biological treatment, mainly directed at key points of the defective VHL/HIF pathway, showed significantly better efficacy in patients of
all prognostic groups with prolonged survival compared to interferon alpha. Currently tyrosinekinase receptor inhibitors for angiogenic
growth factors, sorafenib, sunitinib and pazopanib, monoclonal antibody neutralizing vascular endothelial growth factor bevacizumab
and mTOR kinase inhibitors temsirolimus and everolimus are registered for the first or second-line treatment of advanced and/or metastatic
disease. Axitinib, 2nd generation tyrosinkinase inhibitor is expected to be register.
Keywords: renal cell carcinoma, sorafenib, sunitinib, bevacizumab, pazopanib, everolimus, axitinib
Published: April 1, 2013 Show citation
References
- Novotvary 2007 ČR, ÚZIS ČR 2010. www.svod.cz.
- Hes O, Hora M, Michal M. Nová klasifikace nádorů ledvin dle WHO 2004 - komentovaný přehled. Urol Listy 2004; 3: 40-44.
- Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: Memorial Sloan-Kettering Cancer Center experience. Clin Cancer Res 2004; 10: 6302-6303.
Go to original source... 
Go to PubMed... - Šlampa P, Petera J, et al. Radiační onkologie. 1. Vydání, Praha, Galén a nakladatelství Karolinum 2007.
- Negrier S, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. N Engl J Med 1998; 338: 1273-1278. Go to original source... Go to PubMed...
- Negrier S, Perol D, Ravaud A, et al. Medroxyprogesterone, interferon alfa-2a, interleukin 2 or combination of both cytokines in patients with metastatic renal carcinoma of intermediate prognosis. Cancer 2007; 110: 2448-2457. Go to original source... Go to PubMed...
- Kaelin WG. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002; 2: 673-682. Go to original source... Go to PubMed...
- Melichar B, Procházková-Študentová H, Vitásková D, et al. Bevacizumab in combination with IFN-? in metastatic renal cell carcinoma: the AVOREN trial. Expert Rev Anticancer Ther. 2012; 12(10). Go to original source... Go to PubMed...
- Escudier B, et al. for the TARGET Study Group. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134. Go to original source... Go to PubMed...
- Motzer RJ, Hutson TE, Tomczak P, et al. Overall survival and updated results for sunitinib compared with interferon (IFN) - alfa in patients with metastatic renal cell carcinoma (mRCC), J Clin Oncol 2009; 27: 3584-3590. Go to original source... Go to PubMed...
- Sternberg CN, Davis ID, Mardiak J, et al. Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial J Clin Oncol 2010; 28: 1061-1068. Go to original source... Go to PubMed...
- Motzer R, Hudson TE, Reeves J, et al. Randomized, open-label, phase III trial of pazopanib versus sunitinib in first-line treatment of patients with metastatic renal cell carcinoma (mRCC): results of the COMPARZ trial. Presented at: 2012 European Society for Medical Oncology; Vienna, Austria; October 1, 2012. Abstract LBA 8. Go to original source...
- Escudier B, Porta C, Bono B, et al. Patient preference between pazopanib and sunitinib: Results of a randomized double-blind, placebo-controlled, cross-over study in patients with metastatic renal cell carcinoma - PISCES study, NCT 01064310. ASCO 2012; Abstract CRA4502. Go to original source...
- Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 2011; 378: 1931-1939. Go to original source... Go to PubMed...
- Hudes G, et al. for the Global ARCC Trial. Temsirolimus, interferon-alpha, or both for advanced renal-cell carcinoma. N Engl J Med 2007; 356: 2271-2281. Go to original source... Go to PubMed...
- Motzer R, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008; 372: 449-456. Go to original source... Go to PubMed...
- Büchler T, Klapka R, Melichar, et al. Sunitinib followed by sorafenib or vice versa for metastatic renal cell carcinoma-data from the Czech registry. Ann Oncol. 2012; 23(2): 395-401. Epub 2011 May 2. Go to original source... Go to PubMed...
- Iacovelli R, Santoni M, Di Lorenzo, et al. Progression free survival (PFS) and overall survival (OS) in patients receiving 3 targeted therapies (TTs) for metastatic renal-cell carcinoma (mRCC). Ann Oncol 2012; 23(Suppl. 9). Abstract 818. Go to original source...
- Bhojani N, Jeldres C, Patard JJ, et al. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 2008; 53: 917-930. Go to original source... Go to PubMed...